Email updates

Keep up to date with the latest news and content from Genome Biology and BioMed Central.

Research news

Antisense in Staphylococcus

Jonathan B Weitzman

Author Affiliations

Genome Biology 2001, 2:spotlight-20010921-01  doi:10.1186/gb-spotlight-20010921-01


The electronic version of this article is the complete one and can be found online at:


Published:21 September 2001

© 2001 BioMed Central Ltd

Research news

Although many gene-inactivation technologies have been applied to bacterial genetics, the potential for using antisense technology has not been extensively explored. In the September 21 Science, Yindo Ji and colleagues from GlaxoSmithKline Pharmaceuticals in Collegeville, Pennsylvania, describe a comprehensive genomic analysis of the human pathogen Staphylococcus aureus using a regulated antisense strategy (Science 2001, 293:2266-2269). They used an adapted tetracycline-dependent (tet) regulatory system to drive the expression of small fragments of sheared DNA. Colonies were selected that grew in the absence of anhydrotetracycline but not when expression was induced. About 3% of colonies were growth-defective or lethal upon induction, and about a third of these contained single-ORF antisense constructs. This method allows easy isolation and maintenance of conditional growth-defective strains, and rapid identification of the relevant gene. Ji et al. identified over 150 genes that are critical for growth and survival, and are potential targets for antibiotic discovery. A third of these genes encode for proteins of unknown function. Each of the bacterial strains generated offers a titratible system to investigate the bacterial growth phenotype and the role in infection.

References

  1. An antisense approach to phenotype-based gene cloning in Tetrahymena

    PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  2. [http://www.sciencemag.org] webcite

    Science

  3. [http://www.gsk.com] webcite

    GlaxoSmithKline Pharmaceuticals